Skip to main content
31 December, 2020

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection

Hyris CE-IVD marked test for COVID human diagnostic "bKIT Virus Finder COVID-19" is at the core of the signature Article "Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection", from the Department of Laboratory Medicine of the National Institute for The Study and Treatment of Cancer IRCCS "Fondazione G Pascale" (IRCCS Pascale), of Naples (Italy)

The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. Up to now, laboratory real-time PCR is the standard of care, but requires a fully equipped laboratory and significant infrastructure. Consequently, new diagnostic tools are required.

Professor Leonardo Miscio and his colleagues evaluated the diagnostic accuracy of Hyris point-of-care rapid test "bKIT Virus Finder COVID-19", both by a retrospective and a prospective analysis.

Results obtained are entirely comparable to the standard laboratory-based real-time PCR methods for all the analyzed samples, with a much faster result and no need for an equipped facility.

This authoritative Article furtherly strengthens the Hyris System's relevance for human diagnostic, now empowered via the CE-IVD marked 'bKIT Virus Finder COVID-19', as it represents indeed a promising tool to improve the health surveillance and to increase the overall capacity of SARS-CoV-2 testing.

Hyris System confirms to be a key asset in the global fight against the last Coronavirus.

Read the full article HERE


  • Hyris signs a distribution agreement with GrowBIGogh

  • Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

  • Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

  • Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

  • Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

  • Hyris' new onboarding programs support researchers and developers to launch testing kits.

  • Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

  • Hyris and Singlabs signed a distributorship agreement for Singapore

  • Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

  • Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine